Develops cancer drugs that attack RAS proteins, which drive roughly 30% of human cancers but have long been considered impossible to target.
Erasca is a biotech company trying to treat cancers driven by RAS pathway proteins — a family of mutations that cause roughly 30% of human cancers but whose smooth surface gives conventional drugs nothing to grip. Naporafenib, its lead drug, exploits a narrow structural exception found in NRAS-mutated melanoma cells, and its Phase 3 trial, SEACRAFT-2, is running now to generate the efficacy data regulators require before approval — but because NRAS mutations appear in only 15–20% of melanoma cases, the trial fills one patient at a time as mutation-positive cases naturally arrive at oncology centers, and no amount of additional funding can speed that up. A second drug, ERAS-0015, takes a different approach entirely: instead of trying to block the RAS protein, it acts as a molecular glue that recruits the cell's own disposal machinery to destroy the protein — a mechanism that cannot be replicated by optimizing a standard inhibitor, but whose failure modes also cannot be detected until late-stage human trials. If SEACRAFT-2 fails, Erasca loses not just its only near-term approval pathway but also the clinical proof that RAS inhibition works in humans, which is the single thing that would make ERAS-0015 attractive to any licensing partner willing to fund what comes next.
How does this company make money?
The company currently earns no revenue. All operations are funded by selling equity to investors. Future money would come from licensing deals or an acquisition payment from a larger pharmaceutical company — most likely triggered by positive data from SEACRAFT-2 or a regulatory approval milestone.
What makes this company hard to replace?
Oncologists who want to move patients to a competing RAS program would have to build new relationships with a different trial sponsor and learn a different set of patient-selection rules. Any competitor trying to bring a rival drug to market must complete a full new drug application process with regulators from scratch. Patent protection through 2043 also prevents any competitor from simply reproducing the molecular structures of naporafenib or ERAS-0015.
What limits this company?
NRAS-mutated melanoma affects only 15–20% of all melanoma patients. SEACRAFT-2 can only enroll patients who have that specific mutation, so the trial advances at whatever pace those patients naturally arrive at participating cancer centers. Spending more money or opening more trial sites cannot change how often that mutation occurs in the population.
What does this company depend on?
The company cannot operate without FDA Investigational New Drug approvals for each compound it tests in humans. It relies on contract research organizations to run the day-to-day operations of the SEACRAFT-2 trial. Specialized oncology treatment centers that can perform genetic mutation testing and identify eligible patients are essential to enrollment. Good Manufacturing Practice facilities produce the clinical-grade supply of naporafenib and other pipeline compounds. Composition-of-matter patent protection through 2043 is also a foundational asset the company depends on to defend its molecules.
Who depends on this company?
NRAS-mutated melanoma patients currently enrolled in SEACRAFT-2 would lose access to a potential treatment if the trials were halted. Oncology treatment centers participating in the trial would lose access to investigational RAS pathway drugs for patients who have few other options. Pharmaceutical companies looking to license or acquire validated RAS and MAPK pathway drug programs are watching SEACRAFT-2 as the evidence base for those potential deals.
How does this company scale?
Once the underlying research methods are established, applying them to additional RAS pathway targets — such as ERAS-4001 — is relatively efficient. What does not scale with money is patient recruitment: every trial targeting a genetically defined cancer subset is limited by how often that mutation naturally appears, so enrollment timelines are fixed no matter how much capital is available.
What external forces can significantly affect this company?
FDA policies on orphan drug designation and accelerated approval for rare cancer mutations could shorten the time needed to reach the market. Medicare and private insurance decisions about covering precision oncology treatments will determine whether an approved drug actually generates revenue. Geopolitical restrictions on clinical operations in key countries could reduce the pool of eligible patients available to SEACRAFT-2.
Where is this company structurally vulnerable?
The three-way interaction that ERAS-0015 must trigger cannot be tested with standard lab assays — the only way to know whether it works or causes harm is to run it in humans. If ERAS-0015 fails or causes unexpected side effects in a late-stage human trial, it would undermine the entire scientific idea behind the approach, and with it the company's ability to attract licensing partners for its broader RAS drug portfolio.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph